Sclerostin blood levels before and after kidney transplantation

Kidney and Blood Pressure Research

Volumn 39, Issue 4, 2014, Pages 230-239

  Bonani, Marco ^a   Rodriguez, Daniel ^a,b   Fehr, Thomas ^a   Mohebbi, Nilufar ^a   Brockmann, Jens ^a   Blum, Markus ^a   Graf, Nicole ^c   Frey, Diana ^a   Wüthrich, Rudolf P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Sch of Eng of Winterthur HTL   (Switzerland)

Author keywords

Bone mineral metabolism; Kidney transplantation; Sclerostin

Indexed keywords

BASILIXIMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CINACALCET; COLECALCIFEROL; CYCLOSPORIN; DENOSUMAB; MYCOPHENOLIC ACID; PARATHYROID HORMONE; PHOSPHATE; PREDNISONE; SCLEROSTIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VITAMIN D; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; SOST PROTEIN, HUMAN;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE MINERAL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; ELISA KIT; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; STEROID THERAPY; VITAMIN BLOOD LEVEL; ADVERSE EFFECTS; AGED; BLOOD; CONTROLLED STUDY; FOLLOW UP; GENETIC MARKER; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84906035179     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355781     Document Type: Article

References (34)

1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
2. Ebeling PR: Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab 2009;94:1483-1490.
3. Evenepoel P: Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol 2013;33:191-203.
4. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-2643.
5. Williams BO: Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J Bone Miner Res 2014;29:24-28.
6. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-869.
7. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL: Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010;87:99-107.
8. van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE: Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 2013;28:848-854.
9. Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M: Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012;27:226-230.
10. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D: The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD. Clin J Am Soc Nephrol 2013;8:819-823.
11. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC: Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013;28:3024-3030.
12. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R: Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 2011;96:1159-1162.
13. Sarkar D: Lattice - Multivariate Data Visualization with R. (ISBN 978-0-387-75968-5) New York, Springer, 2008.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009. DOI 10.1038/ki.2009.188.
15. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH: Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011;6:877-882.
16. Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M: Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014;99:2482-55.
17. Jean G, Chazot C: Sclerostin in CKD-MBD: one more paradoxical bone protein? Nephrol Dial Transplant 2013;28:2932-2935.
18. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH: Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/ sclerostin. J Biol Chem 2008;283:5866-5875.
19. Brabnikova Maresova K, Pavelka K, Stepan JJ: Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 2013;92:354-361.
20. Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P: Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 2013;57:272-276.
21. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE: Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 2012;97:2012-2218.
22. Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov, II: Serum extracellular secreted antagonists of the canonical Wnt/beta-catenin signaling pathway in patients with Cushing's syndrome. Osteoporos Int 2013;24:2191-2199.
23. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, 3rd, Khosla S: Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373-379.
24. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A: Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012;97:148-154.
25. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-4583.
26. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ: Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 2011;96:2011-1534.
27. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD: Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2013;24:489-494.
28. Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Adami S, Rossini M: Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 2012;27:2259-2263.
29. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C: Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-588.
30. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C: Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-959.
31. Padhi D, Jang G, Stouch B, Fang L, Posvar E: Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
32. Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G: Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, doubleblind, placebo-controlled study. J Clin Pharmacol 2014;54:168-178.
33. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG: Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med 2014;370:412-420.
34. McColm J, Hu L, Womack T, Tang CC, Chiang AY: Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014;29:935-943.